Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year High at $14.89

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report)'s stock price reached a new 52-week high on Wednesday . The stock traded as high as $14.89 and last traded at $14.89, with a volume of 1608924 shares traded. The stock had previously closed at $13.95.

Wall Street Analyst Weigh In

TEVA has been the subject of several research reports. The Goldman Sachs Group lifted their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research note on Monday, February 5th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 1st. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an "overweight" rating in a research note on Monday, February 5th. Piper Sandler upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Finally, Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and increased their price target for the stock from $10.00 to $14.00 in a research report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $13.78.

Teva Pharmaceutical Industries Stock Performance

The company has a market cap of $17.64 billion, a price-to-earnings ratio of -33.13, a PEG ratio of 1.67 and a beta of 1.04. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23. The stock has a 50 day simple moving average of $13.64 and a 200 day simple moving average of $11.69.

Insiders Place Their Bets

In related news, CEO Richard D. Francis sold 74,530 shares of the company's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the sale, the chief executive officer now directly owns 87,125 shares of the company's stock, valued at $1,145,693.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the completion of the transaction, the chief executive officer now owns 87,125 shares of the company's stock, valued at $1,145,693.75. The disclosure for this sale can be found here. Insiders have sold 358,972 shares of company stock worth $4,739,820 in the last quarter. 0.55% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently made changes to their positions in the stock. Commonwealth Equity Services LLC grew its position in shares of Teva Pharmaceutical Industries by 5.2% during the third quarter. Commonwealth Equity Services LLC now owns 255,477 shares of the company's stock worth $2,606,000 after acquiring an additional 12,587 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Teva Pharmaceutical Industries by 1.1% in the third quarter. Bank of New York Mellon Corp now owns 1,902,235 shares of the company's stock valued at $19,403,000 after purchasing an additional 19,906 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Teva Pharmaceutical Industries by 9.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 412,277 shares of the company's stock worth $4,205,000 after buying an additional 34,623 shares during the last quarter. Strs Ohio raised its holdings in shares of Teva Pharmaceutical Industries by 84.1% during the 3rd quarter. Strs Ohio now owns 617,938 shares of the company's stock valued at $6,302,000 after purchasing an additional 282,300 shares in the last quarter. Finally, IFM Investors Pty Ltd boosted its stake in shares of Teva Pharmaceutical Industries by 2.8% during the 3rd quarter. IFM Investors Pty Ltd now owns 183,771 shares of the company's stock worth $1,874,000 after acquiring an additional 5,075 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.